ICAM3 (Intercellular Adhesion Molecule 3), a member of the immunoglobulin superfamily, is a transmembrane glycoprotein predominantly expressed on leukocytes, including T cells, neutrophils, and dendritic cells. It plays a critical role in immune responses by mediating cell-cell interactions through binding to integrins like LFA-1 (Lymphocyte Function-associated Antigen-1). ICAM3 is involved in T-cell activation, leukocyte migration, and antigen presentation, facilitating immune surveillance and inflammatory processes. Its structure includes five extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail that may participate in intracellular signaling.
ICAM3 antibodies are essential tools for studying its biological functions and therapeutic potential. By blocking ICAM3-LFA-1 interactions, these antibodies can modulate immune responses, offering insights into treating autoimmune diseases or inflammation. Additionally, ICAM3 is overexpressed in certain cancers, making it a potential biomarker or target for immunotherapy. Antibodies against ICAM3 are widely used in research applications such as flow cytometry, immunohistochemistry, and functional assays to explore its expression patterns and mechanistic roles. Recent studies also highlight its involvement in HIV-1 infection, as ICAM3 on dendritic cells enhances viral transfer to T cells. Thus, ICAM3 antibodies hold promise for both basic research and clinical development in immunology and oncology.